antibodies -online.com





anti-Interleukin 17a antibody





Go to Product page

| \sim | | | | |
|--------|-----|--------|----|-----|
| () | 10 | K\ / I | 01 | A / |
| 1 1 | ve. | I \/ I | -1 | /\/ |
| | | | | |

| Quantity: | 0.1 mg |
|-------------------|---|
| Target: | Interleukin 17a (IL17A) |
| Reactivity: | Human |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Conjugate: | This Interleukin 17a antibody is un-conjugated |
| Application: | ELISA, Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunoprecipitation (IP) |
| Product Details | |
| Purpose: | Anti-Hu IL-17A Purified |
| Immunogen: | mammalian-derived human IL-17-IgG fusion protein, boost with recombinant human IL-17A |
| Clone: | 9F9 |
| Isotype: | IgG1 kappa |
| Specificity: | The mouse monoclonal antibody 9F9 recognizes human interleukin 17A (IL-17A, secreted or intracellular). |
| Purification: | Purified by protein-A affinity chromatography. |
| Target Details | |
| Target: | Interleukin 17a (IL17A) |
| Alternative Name: | IL-17A (IL17A Products) |

Target Details

| Background: |
|---------------|
| Dading Carra. |

Interleukin 17A,Interleukin 17A (IL-17A) is a proinflammatory cytokine produced by activated T cells. IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides, and remodeling proteins. It plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. It is the signature effector cytokine of Th17 cells, and in this role it primarily induces neutrophil activation and recruitment at infection and inflammatory sites. High levels of IL-17A are associated with rheumatoid arthritis, psoriasis, multiple sclerosis, and another inflammatory diseases, including lung injugy during severe COVID 19. This cytokine also contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells. It is an effector cytokine for invariant NKT cells (iNKT), and it is involved in epithelial barrier formation upon injury.,Interleukin 17

Gene ID:

3605

UniProt:

Q16552

Application Details

| /\nnli | notter | NIATAC |
|--------|--------|--------|
| Applic | alion | Notes |


Flow cytometry: Recommended dilution: 0.5-4 µg/mL. Intracellular staining.


Restrictions:


For Research Use only

Handling

| Concentration: | 1 mg/mL |
|--------------------|--|
| Buffer: | Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
| Preservative: | Sodium azide |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage: | 4 °C |
| Storage Comment: | Store at 2-8°C. Do not freeze. |







Flow Cytometry

Image 1. Separation of human CD4 positive IL-17A positive lymphocytes (red-filled) from CD4 negative IL-17A negative lymphocytes (black-dashed) in flow cytometry analysis (intracellular staining) of human PHA stimulated and Brefeldin A treated peripheral whole blood stained using anti-human IL-17A (9F9) purified antibody (concentration in sample 0,5 μ g/mL, GAM APC).

Flow Cytometry

Image 2. Flow cytometry multicolor intracellular staining of PHA stimulated and Brefeldin A treated peripheral whole blood showing lymphocytes stained using anti-human CD4 (MEM-241) PE-Cy™7 antibody (4 µL reagent / 100 µL of peripheral whole blood) and anti-human IL-17A (9F9) purified antibody (concentration in sample 0,5 µg/mL, GAM APC).

Flow Cytometry

Image 3. Flow cytometry intracellular staining pattern of human PHA stimulated and Brefeldin A treated peripheral whole blood stained using anti-human IL-17A (9F9) purified antibody (concentration in sample 0,5 μ g/mL, GAM APC).